Cardinal Health, Inc. (BIT:1CAH)
Italy · Delayed Price · Currency is EUR | Market Cap | 55.16B +36.6% |
| Revenue (ttm) | 226.98B +10.0% |
| Net Income | 1.60B +14.0% |
| EPS | 6.93 +16.5% |
| Shares Out | n/a |
| PE Ratio | 29.09 |
| Forward PE | 20.39 |
| Dividend | 1.79 (0.89%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | n/a |
| Open | 201.60 |
| Previous Close | 203.40 |
| Day's Range | 201.60 - 201.60 |
| 52-Week Range | 131.10 - 217.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 5, 2026 |
About Cardinal Health
Cardinal Health, Inc. operates as a healthcare services and products company in the United States and internationally. It operates in two segments: Pharmaceutical and Specialty Solutions, and Global Medical Products and Distribution. The company offers customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. It distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. T... [Read more]
Financial Performance
In fiscal year 2026, Cardinal Health's revenue was $254.25 billion, an increase of 14.23% compared to the previous year's $222.58 billion. Earnings were $1.71 billion, an increase of 9.80%.
Financial numbers in USD Financial StatementsNews
Cardinal Health participates in a conference call with JPMorgan
JPMorgan holds a post 3Q earnings conference call with management on November 6 at 2 pm. Webcast Link
Cardinal Health price target raised to $295 from $276 at RBC Capital
RBC Capital analyst Ryan Halsted raised the firm’s price target on Cardinal Health (CAH) to $295 from $276 and keeps an Outperform rating on the shares. The firm cites the…
Cardinal Health price target raised to $310 from $295 at UBS
UBS raised the firm’s price target on Cardinal Health (CAH) to $310 from $295 and keeps a Buy rating on the shares.
Cardinal Health price target raised to $306 from $286 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Cardinal Health (CAH) to $306 from $286 and keeps an Overweight rating on the shares.
Cardinal Health price target raised to $290 from $280 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $290 from $280 and keeps an Outperform rating on the shares.
Cardinal Health price target raised to $305 from $276 at Baird
Baird analyst Eric Coldwell raised the firm’s price target on Cardinal Health (CAH) to $305 from $276 and keeps an Outperform rating on the shares. The firm updated its model…
Cardinal Health price target raised to $290 from $280 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $290 from $280 and keeps an Outperform rating on the shares. Following the fiscal Q1 report, the firm increased…
Cardinal Health price target raised to $305 from $276 at Baird
Baird raised the firm’s price target on Cardinal Health (CAH) to $305 from $276 and keeps an Outperform rating on the shares.
Cardinal Health Earnings Call Transcript: Q1 2027
Q1 revenue, operating income and EPS increased, prompting higher FY27 EPS guidance. Pharma and growth businesses led; GMPD remains focused on operational improvements amid petroleum cost pressure.
Cardinal Health Slides: Q1 2027
Cardinal Health has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on November 5, 2026.
Cardinal Health Earnings release: Q1 2027
Cardinal Health released its Q1 2027 earnings on November 5, 2026, summarizing the period's financial results.
Cardinal Health Quarterly report: Q1 2027
Cardinal Health has published its Q1 2027 quarterly earnings report on November 5, 2026.
Cardinal Health raises FY27 EPS view to $12.80-$13.00 from $12.40-$12.60
Consensus $12.56. The company said, “Cardinal Health (CAH) is raising its fiscal year 2027 guidance for non-GAAP diluted EPS to $12.80 to $13.00, from the previous range of $12.40 to…
Cardinal Health reports Q1 EPS $3.26, consensus $2.94
Reports Q1 revenue $67.51B, consensus $66.51B. “Our results reflect a strong start to fiscal 2027 and demonstrate consistent execution against our strategic priorities,” said Jason Hollar, CEO of Card...
Cardinal Health Reports First Quarter Fiscal Year 2027 Results and Raises Outlook
First quarter revenue increased 5% to $67.5 billion GAAP 1 operating earnings increased 13% to $753 million; GAAP diluted EPS increased 27% to $2.38 Non-GAAP operating earnings increased 17% to $1.0 b...
Cardinal Health price target raised to $286 from $265 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on Cardinal Health (CAH) to $286 from $265 and keeps an Overweight rating on the shares.
Cardinal Health, McKesson awarded $2.7B and $741.5M DLA contracts respectively
Cardinal Health (CAH) and McKesson (MCK) have each been awarded fixed-price, indefinite-delivery/indefinite-quantity contracts worth $2.7B and $741.5M respectively under a solicitation for the Medical...
Cardinal Health price target raised to $280 from $250 at Mizuho
Mizuho raised the firm’s price target on Cardinal Health (CAH) to $280 from $250 and keeps an Outperform rating on the shares. The firm adjusted targets in the drug distributor…
Cardinal Health price target raised to $295 from $280 at UBS
UBS analyst Kevin Caliendo raised the firm’s price target on Cardinal Health (CAH) to $295 from $280 and keeps a Buy rating on the shares.
CVS extensions ‘a clearing event’ for McKesson, Cardinal Health, says BofA
BofA reiterates Buy ratings on McKesson (MCK) and Cardinal Health (CAH) after both companies announced deals to extend distribution agreements with CVS Health (CVS). The extension of the CVS contracts...
Cardinal Health enters LOI to extend distribution agreements with CVS Health
Cardinal Health (CAH) has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health (CVS) through June 30, 2032, reflecting the continuation of Cardinal…
Cardinal Health reaffirms FY27 non-GAAP EPS view $12.40-$12.60, consensus $12.57
In connection with the renewal, Cardinal Health (CAH) has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth, or $12.40 to $12.60, and its long-term non-GAAP…
Cardinal Health Enters into Binding Letter of Intent to Extend Pharmaceutical Distribution Agreements with CVS Health
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that it has entered into a binding Letter of Intent to extend its existing distribution agreement with CVS Health...
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2027 on November 5
DUBLIN, Ohio, Oct. 1, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release first-quarter financial results for its fiscal year 2027 on November 5, prior to the opening of trading on the N...